CLINICAL OUTCOMES WITH FIRST-LINE BEVACIZUMAB AND CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER AND A HISTORY OF DIABETES: RESULTS FROM THE ARIES OBSERVATIONAL COHORT STUDY

被引：1
|
作者：
Bendell, J. [1 ]
Cohn, A. [2 ]
Mun, Y. [3 ]
Fish, S. [3 ]
Sommer, N. [3 ]
Grothey, A. [4 ]
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Rocky Mt Canc Ctr, Denver, CO USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Mayo Clin, Coll Med, Div Med Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu164.10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 0010
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)
    Kozloff, M.
    Hainsworth, J.
    Badrinath, S.
    Cohn, A.
    Flynn, P.
    Steis, R.
    Dong, W.
    Suzuki, S.
    Sarkar, S.
    Sugrue, M.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [32] Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
    Muro, Kei
    Itabashi, Michio
    Hashida, Hiroki
    Masuishi, Toshiki
    Bando, Hiroyuki
    Denda, Tadamichi
    Yamanaka, Takeharu
    Ohashi, Yasuo
    Sugihara, Kenichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (04) : 339 - 346
  • [33] Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis
    Hu, W.
    Xu, W. -S.
    Liao, X. -F.
    He, H. -J.
    MINERVA CHIRURGICA, 2015, 70 (06) : 451 - 458
  • [34] Optimizing the Efficacy of First-Line Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer
    Shaotang Li
    Pan Dr Chi
    BioDrugs, 2011, 25 : 43 - 50
  • [35] Prognostic factors of metastatic colorectal cancer patients undergoing first-line chemotherapy plus bevacizumab
    Bousahba, A.
    Behourah, Z.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment
    Long Bai
    Dong-sheng Zhang
    Wen-jing Wu
    Chao Ren
    De-shen Wang
    Feng Wang
    Miao-zhen Qiu
    Rui-hua Xu
    Medical Oncology, 2015, 32
  • [37] Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment
    Bai, Long
    Zhang, Dong-sheng
    Wu, Wen-jing
    Ren, Chao
    Wang, De-shen
    Wang, Feng
    Qiu, Miao-zhen
    Xu, Rui-hua
    MEDICAL ONCOLOGY, 2015, 32 (02)
  • [38] A prospective, multicenter, observational study of bevacizumab in combined with chemotherapy as first-line or second-line treatment in Chinese metastatic colorectal cancer
    Qin, Shukui
    Deng, Yanhong
    Bi, Feng
    Liu, Tian Shu
    Liu, Yunpeng
    Zhang, Suzhan
    Xu, Jianming
    Shu Yongqian
    Xu, Nong
    Wu, Changping
    Wang, Xin
    Zhong, Haijun
    Feng, Jifeng
    He, Yulong
    Yang, Jianwei
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [39] Bevacizumab and First-line Chemotherapy for Older Patients with Advanced Colorectal Cancer: Final Results of a Community-based Observational Italian Study
    Lutrino, Stefania Eufemia
    Bergamo, Francesca
    Schirripa, Marta
    Rosati, Gerardo
    Avallone, Antonio
    Giampieri, Riccardo
    Cordio, Stefano
    Berretta, Massimiliano
    Llimpe, Fabiola Rojas
    Pisa, Federica Edith
    Lonardi, Sara
    Loupakis, Fotios
    Fasola, Gianpiero
    Aprile, Giuseppe
    ANTICANCER RESEARCH, 2015, 35 (04) : 2391 - 2399
  • [40] SINGLE INSTITUTION RESULTS OF FIRST-LINE TREATMENT WITH BEVACIZUMAB PLUS CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER (MCRC)
    Barkmanova, Jaroslava
    Petruzelka, Lubos
    Sedlackova, Eva
    Vocka, Michal
    Hejduk, Karel
    Bortlicek, Zbynek
    ANNALS OF ONCOLOGY, 2014, 25
12345